Millennium Management’s Processa Pharmaceuticals PCSA Stock Holding History

Millennium Management’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-52	Closed	-$6.61K	–	6414
2023 Q3	$6.61K	Sell	52 -18	-26%	-$3.4K	﹤0.01%	5831
2023 Q2	$17.5K	Sell	70 -31	-31%	-$9.16K	﹤0.01%	5655
2023 Q1	$27K	Buy	+101	New	+$40.7K	﹤0.01%	5791
2021 Q3	–	Sell	-108	Closed	-$444K	–	7124
2021 Q2	$444K	Sell	108 -80	-43%	-$309K	﹤0.01%	5406
2021 Q1	$1.02M	Sell	188 -26	-12%	-$121K	﹤0.01%	4202
2020 Q4	$705K	Buy	+214	New	+$594K	﹤0.01%	3957

Other funds holding PCSA

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Spinnaker Trust Portland, Maine $1.81B AUM 17.83% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management's PCSA Position: Q4 2023 in Review

Millennium Management sold out of Processa Pharmaceuticals (PCSA) in Q4 2023, closing a stake of 52 shares — an estimated $6.61K sold.

Millennium Management first reported a position in PCSA in Q4 2020 and held it in 6 quarters. The position peaked at $1.02M in Q1 2021. 18 funds tracked by Wall St. Rank hold PCSA as of Q4 2023.

Millennium Management reported no remaining Processa Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Millennium Management sold 52 Processa Pharmaceuticals shares in Q4 2023, an estimated $6.61K.
Millennium Management first reported a position in Processa Pharmaceuticals in Q4 2020 and held it in 6 quarters.
Millennium Management's Processa Pharmaceuticals position peaked at $1.02M in Q1 2021.
18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.